Eloxx Pharmaceuticals Inc ELOX:NASDAQ

Last Price$0.25NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/01/22

Today's Change0(0.00%)
Bid (Size)$0.25 (7)
Ask (Size)$0.25 (15)
Day Low / HighN/A - N/A
Volume123.0 K
 

View Biotechnology IndustryPeer Comparison as of 07/01/2022

 

Eloxx Pharmaceuticals Inc ( NASDAQ )

Price: $0.25
Change: -0.02 (7.30%)
Volume: 123.0 K
4:00PM ET 7/01/2022
 
 

Idera Pharmaceuticals Inc ( NASDAQ )

Price: $0.44
Change: -0.02 (4.58%)
Volume: 83.5 K
4:00PM ET 7/01/2022
 
 

Yumanity Therapeutics Inc ( NASDAQ )

Price: $1.84
Change: +0.02 (1.10%)
Volume: 195.8 K
4:00PM ET 7/01/2022
 
 

Timber Pharmaceuticals Inc ( NYSE MKT LLC )

Price: $0.30
Change: -0.01 (3.34%)
Volume: 413.9 K
8:00PM ET 7/01/2022
 
 

Soligenix Inc ( NASDAQ )

Price: $0.58
Change: -0.02 (3.20%)
Volume: 67.5 K
4:00PM ET 7/01/2022
 

Read more news Recent News

--Piper Sandler Adjusts Eloxx Pharmaceuticals' Price Target to $1.50 from $4, Keeps Overweight Rating
10:06AM ET 5/23/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--HC Wainwright Trims Eloxx Pharmaceuticals Price Target to $0.5 From $1, Maintains Neutral Rating
11:23AM ET 5/09/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Top Premarket Decliners
7:57AM ET 4/07/2022 MT Newswires

Aptinyx (APTX) shares slumped 51% after the company said its phase 2b trial in painful diabetic peripheral neuropathy failed to meet its primary endpoint....

Eloxx Pharmaceuticals Obtains Funding of Up to About $16 Million From Cystic Fibrosis Foundation
8:16AM ET 3/29/2022 MT Newswires

Eloxx Pharmaceuticals (ELOX) said Tuesday it has obtained funding of up to $15.9 million from the Cystic Fibrosis Foundation to support its ongoing...

View all Commentary and Analysis

No news stories available at this time.

Company Profile

Business DescriptionEloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. Its lead product candidate is ELX-02, a small molecule drug designed to restore production of full-length functional proteins. It operates through the United States and Israel geographical segments. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Watertown, MA. View company web site for more details
Address480 Arsenal Way
Watertown, Massachusetts 02451
Phone+1.781.577.5300
Number of Employees29
Recent SEC Filing06/17/20224
President, Chief Executive Officer & DirectorSumit Aggarwal
Chief Financial & Accounting OfficerDaniel E. Geffken
Head-Research & DevelopmentVijay Modur
Chief Medical OfficerAli Hariri

Company Highlights

Price Open$0.26
Previous Close$0.27
52 Week Range$0.21 - 2.03
Market Capitalization$21.7 M
Shares Outstanding86.7 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/15/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.70
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-258.67%

Analyst Ratings as of 06/30/2022

Buy
2
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset